Alpha Omega Wealth Management LLC Sells 150 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Alpha Omega Wealth Management LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,276 shares of the biopharmaceutical company’s stock after selling 150 shares during the period. Alpha Omega Wealth Management LLC’s holdings in Gilead Sciences were worth $3,911,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GILD. PCA Investment Advisory Services Inc. bought a new stake in Gilead Sciences during the second quarter worth about $25,000. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Tompkins Financial Corp lifted its stake in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock traded up $0.02 during trading on Wednesday, reaching $67.33. The company’s stock had a trading volume of 2,167,063 shares, compared to its average volume of 7,275,677. Gilead Sciences, Inc. has a 1 year low of $66.95 and a 1 year high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $83.83 billion, a P/E ratio of 14.96, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. The company’s fifty day moving average is $72.40 and its 200-day moving average is $76.73.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.67 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.57%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GILD. Oppenheimer lowered their target price on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. Wells Fargo & Company reduced their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Mizuho dropped their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Finally, Barclays dropped their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. One analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $85.36.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.29% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.